Brogan, A.J., J.D. Miller, S.E. Talbird, J. Thompson, and B. Deniz. Long-term Clinical Value of Telaprevir for Treatment of Treatment-naïve and Treatment-experienced Patients with Hepatitis C Virus Infection: Projections Using Decision-analytic Modeling.

Chirila, C., T.M. Gilligan, A. Gilsenan, M. Price, K. Hollis, B. Calingaert, L. Zografos, and E. Andrews. A Comparison of Factors Influencing Patient Knowledge: Results Across Selected REMS Surveys.

Midkiff, K., D.H. Harris, A. Gilsenan, Y. Wu, and E. Andrews. Drug Safety Studies Using Cancer Registry Data: Confluence of Elements Impacting the Interview Response Rate.

Gilsenan, A., K. Hollis, L. Zografos, B. Calingaert, and E. Andrews. Examination of Respondent Bias and Patient Characteristics in Multiple REMS Assessment Surveys.

Johannes, C., E. Andrews, L. McQuay, M. Frohlich, and R. Sims. Incidence of Cerebrovascular Accidents in Men With Prostate Cancer.

Gilsenan, A., D.H. Harris, K. Midkiff, J. Wright, and E. Andrews. Linking With Multiple State Cancer Registries for Safety Surveillance Study – Is it Feasible?.

Hollis, K., B. Calingaert, T.M. Gilligan, C. Sweeney, M. Price, S. Perez-Gutthann, and E. Andrews. Quinolones REMS Evaluation Surveys.

Castellsague, J., F. Pisa, V. Rosolen, N. Riera-Guardia, M. Giangreco, E. Clagnan, F. Tosolini, L. Zanier, F. Barbone, and S. Perez-Gutthann. Use of Nimesulide, Other NSAIDs, and the Risk of Upper Gastrointestinal Complications in Friuli Venezia Giulia, Italy.

Pisa, F., D. Drigo, N. Riera-Guardia, J. Castellsague, V. Rosolen, E. Clagnan, F. Tosolini, L. Zanier, S. Perez-Gutthann, and F. Barbone. Validation of Primary and Secondary ICD9CM codes for Upper Gastrointestinal Complications in Friuli Venezia Giulia, Italy.

Mitra, D., P. Trask, S. Iyer, S. Candrilli, and J. Kaye. A Multi-country Retrospective Study of Patient Characteristics and Treatment Patterns in Chronic Myeloid Leukemia.

Sood, V., L. Braun, S. Hogue, K. Davis, C. Copley-Merriman, and B. Lieberman. Chronic Kidney Disease Burdens Patients, Health Care Systems, and Employers.

Spinner, D.S., D. Mladsi, J. Walter, R. Ziemiecki, M. Stafford-Smith, J. Taekman, and E. Faulkner. Clinical Trial Learning Curves May Impact Both Clinical and Economic Outcomes and Influence Health Technology Assessment and Reimbursement Decision Making.

Earnshaw, S.R., C.L. McDade, G. Zanotti, R. Farkouh, and D. Strutton. Cost-effectiveness of 2+1 Dosing of 13-Valent Pneumococcal Conjugate Vaccine Compared With 2+1 Dosing of 10-Valent Conjugate Vaccine in Preventing Pneumococcal Disease in Canada.

Clark, M., A. Hofmann, M. Tabberer, and S. Martin. Development and Content Validity of the COPD Device Preference Questionnaire.

Mohamed, A.F., F. Johnson, B. Hauber, B. Lescrauwaet, and M. Saylan. Do Patients and Physicians Have Similar Preferences for Chronic Hepatitis B Treatment Outcomes in Turkey?.

Hicks, K.A., S. Karve, A. Vlahiotis, S. Frazee, Y. Tian, and S.R. Earnshaw. Estimation of Increases in Direct Medical Expenditures Associated With Medication Nonadherence and Potential Savings From Increased Adherence.

Stull, D., and K. Houghton. Examining Variability in Depression Among Pre-Retirees: Innovative Analytic Methods Applied to Observational Data.

Gonzalez, J., R Johnson, M.C. Runken, and C. Poulos. Generalized Healthy-Time Equivalentsfor Migraine-Treatment Outcomes From Choice-Experiment Trade-off Preferences.

Hauber, B., S. Han, J.C. Yang, I. Gantz, K. Tunceli, J. Gonzalez, K. Brodovicz, C. Alexander , M. Davies, K. Lento, Q. Zhang, and L. Radican. How Much Do Patients with Type 2 Diabetes Value Improvements in Dosing Convenience? Results From a Conjoint Study.

Johal, S., C. Knight, M.J. Bell, and S. Ralston. Long-Term Fiscal Implications of MEPACT in the Treatment of High-Grade Nonmetastatic Osteosarcoma: A Budget-Impact Model and a Lifetime Tax Perspective.

Bridges, J.F.P., A. Mohamed, A. Woehl, H. Finnern, and B. Hauber. Patient Preferences for Non-Small Cell Lung Cancer Treatments.

Palsgrove, A., K. Houghton , A. Hareendran, M. Schaefer, J. Setyawan, M. Mocarski, R. Carson, and B. Make. The Development of the Early Morning Symptoms of COPD Instrument (EMSCI).

Mitra, D., and S.D. Candrilli. Acute Lymphocytic Leukemia–Related Inpatient Care Among Pediatric Patients in the United States.

Lancon, C., D.B. DiBenedetti, S.E. Lewis, K.A. David, N. Danchenko, and C. François. Assessing the Impact of Major Depressive Disorder (MDD) on Family Functioning: Development of the Depression and Family Functioning Scale.

Spinner, D.S., J.W. Walter, M.A. Vazquez-Gragg, T. Bloise, M. Stafford-Smith, E. Faulkner, and J. Taekman. Clinical Trial Learning Curves Affect Outcomes Measurement, Patient Safety, and Trial Success: Contributing Factors and a Potential Solution in Clinical Trial Simulation.

Bell, M.J., J.D. Miller, M. Namjoshi, and M.W. Russell. Comparative Budget Impact of Formulary Inclusion of Zoledronic Acid and Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases.

Candrilli, S.D., S.J. Karve, and P.E. Wirth. Complications Arising During Hospitalization for Hemorrhagic or Ischemic Stroke: Evidence From a Large Administrative Database.

Svedsäter, H., J. Locklear, S. Johal, and I. Özer-Stillman. Cost-effectiveness and budget impact of adjunct quetiapine fumarate extended-release in patients with major depressive disorder with an inadequate response to previous therapy.

Lukac, M., C. Knight, J. Bielik, D. Tomek, V. Foltán, M. Bojnický, and A. Kovac. COST-UTILITY ANALYSIS OF DIENOGEST VERSUS GnRH ANALOGUE IN THE TREATMENT OF ENDOMETRIOSIS-ASSOCIATED PELVIC PAIN IN SLOVAKIA.

Lescrauwaet, B., A.F. Mohamed, F.R. Johnson, and A.B. Hauber. Do Patients and Physicians Have Similar Preferences for Health Care Decisions Involving Uncertain Outcomes for Chronic Hepatitis B in Germany and Turkey?.

Coon , C.D., L.D. Mcleod, L.M. Arnold, A. Chandran, and S. Martin. Evaluating the Screening Ability of Patient-Reported Outcome Instruments.

Faulkner, E., D.S. Spinner, and M. Fernandez. Health outcomes and economic research for cellular therapies and regenerative medicines: Lessons from a US Health Technology Assessment and Reimbursement Analysis.

Coleman, C., S. Chang, K. Copley-Merriman, C.J. Masaquel, and J. Hubble. Health-Related Quality-of-Life Improvements With Dysport in Cervical Dystonia.

Meyers, J.L., and S. Meyers. Inpatient Costs of Low Birth Weight and Pre-Term Infant Stays in the United States in 2008.

Dalal, A.A., L. Nelson , T.M. Gilligan, L.D. Mcleod, S.E. Lewis, and C. DeMuro. Measurement Comparability Between Paper and Alternate Versions: Recommended Assessment Steps Using the Lung Function Questionnaire as an Example.

Garrison, L., B. Levitan, and F.R. Johnson. Pharmaceutical Benefit-Risk Assessment: What Should We Do in the Absence of Regulatory Guidance?.

Knight, S., A. Mohamed, F. Johnson, D.A. Marshall, U. Ladabaum, K. Phillips, and J.M.E. Walsh. Preferences for Genetic Testing to Assess Colon Cancer Risks.

Mordin, M., M. Clark, C. DeMuro, E.D. Evans, K. Copley-Merriman, S. Fehnel, and A. Gnanasakthy. PRO label claims: an analysis based on a review of PROs among NMEs and BLAs 2006–2010.

DeMuro, C., M. Mordin, E.D. Evans, K. Copley-Merriman, S. Fehnel, and A. Gnanasakthy. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010.

Mauskopf, J., C. Chirila, C.J. Masaquel, K.S. Boye, L. Bowman, J. Birt, and D.B. Grainger. The Relationship Between Financial Impact and the Likelihood of Drug Reimbursement in the Australian Health Care System.

Gilligan, T.M., L. Nelson , A.A. Dalal, and L.D. Mcleod. Visually Evaluating the Measurement Comparability Between Paper-Based and Alternate Versions of Administration of the Lung Function Questionnaire.

Amonkar, M.M., B. Sherrill, and X. Zhou. A Review of the Impact of Lapatinib on Health-Related Quality of Life of Patients With Newly Diagnosed and Refractory Metastatic Breast Cancer.

Chung, R.T., A. Bisceglie, F.F. Poordad, T. Hassanein, X. Zhou, E. Lentz, A. Prabhakar, and F.M. Hamzeh. Association of Host Pharmacodynamic Effects and Virologic Response to Peginterferon Alfa-2a/Ribavirin in Patients with Chronic Hepatitis C.

Nicandro, J., P. Tennis, P. Shin, P. Hickman, L. Bennett, K.A. Hollis, and E. Andrews. ONE-YEAR TREATMENT CONTINUATION WITH ALOSETRON IS HIGH IRRESPECTIVE OF IBS-D SEVERITY CRITERIA.

Chirila, C., D. Odom, G. Devercelli, S. Khan, B. Sherif, J. Kaye, I. Molnar, and B. Sherrill. Meta-Analysis of the Validity of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Metastatic Colorectal Cancer Trials.

Faulkner, E., M. Burken, L. Kelley, and R. Richner. Market Access Challenges for Device and Diagnostic Companies: Adaptive Approaches for Value Characterization.

Midkiff, K., A. Gilsenan, Y. Wu, D. Masica, and E. Andrews. Characteristics of Adult Osteosarcoma Patients: Results From an Ongoing Postmarketing Drug Safety Surveillance Study.

Williams, V.S.L., R.T. Carson, L.M. Nelson, J. MacDougall, S.E. Fehnel, B. Lewis, and J.M. Johnston. Application of Exploratory Factor Analysis to Support the Conceptual Framework of PRO Measures: Results From a Phase 2 Study of Irritable Bowel Syndrome With Constipation.

Norquist, J.M., C.J. Girman, S. Fehnel, C. DeMuro, and N. Santanello. Choice of Recall Period for Patient-Reported Outcome Measures: Criteria for Consideration.

Gilsenan, A., E. Andrews, and K.A. Hollis. Characterization of Current Risk Evaluation and Mitigation Strategies.

Tennis, P., K.J. Rothman, R. Bohn, H. Tan, M.S. Anthony, A. Zavras, and B. Calingaert. Multiple Myeloma and IV Bisphosphonate Are Risk Factors for Osteonecrosis of the Jaw.

Hollis, K.A., P. Tennis, J. Nicandro, E. Chuang, C.T. Sweeney, L. Bennett, and E. Andrews. Temporal Trends in Compliance With the Alosetron Risk Management Program.

Hollis, K.A., B. Calingaert, M. Price, E. Andrews, L. Moy, M. Kooijmans, L. Cristiano, and C. Bozic. Tysabri TOUCH Prescriber Program Risk Management Program (RiskMAP) Surveys.

Rycroft, C.E., I.V. Pearson, S. Khan, and A.E. Heyes. A Tale of Four Countries: Comparing Reimbursement Submission Requirements in Ireland, England, Wales, and Scotland.

Rycroft, C.E., O. Leeuwenkamp, T. Heikkinen, N. Principi, J. Herz, A. Moren, and S.M. Beard. Economic and Clinical Burden of Paediatric Influenza in Nine European Countries.

Candrilli, S.D., S.H. O'Brien, and R. Balkrishnan. Economic Outcomes Associated With Hydroxyurea Adherence Among Pediatric Medicaid Enrollees With Sickle Cell Disease.

Fehnel, S., C.M. Ervin, B. Lewis, R.T. Carson, and J.M. Johnston. Identifying Endpoints for Irritable Bowel Syndrome (IBS) Clinical Trials: Incorporating the Patient’s Voice.

Johnson, R, A.F. Mohamed, A. Hauber, and B. Lescrauwaet. Is it Possible to Obtain Willingness-to-Pay Estimates in Europe? A Validity Test of Stated Preferences for Hepatitis B Treatments.

Karve, S., D. Misurski, J.M. Miller, and K.L. Davis. Long-Term Economic and Clinical Burden of Complicated Invasive Meningococcal Disease: Evidence From a United States Managed Care Population.

Meyers, J., and S.D. Candrilli. Patient Characteristics and Charges Associated With Emergency Department Visits Among Patients With a Diagnosis of Restless Legs Syndrome.

Mohamed, A.F., R Johnson, B. Hauber, A. Masterson, and B. Lescrauwaet. Patient Preferences for Benefits, Risks, and Weight of Evidence Associated With Hepatitis B Treatments.

Johnson, F.R., J. Gonzalez, and B. Hauber. Patients’ Stated Health Outcome Preferences for Confounded Patient-Reported Outcome Domains for Osteoarthritis.

Bridges, J.F.P., S. Taylor, N. Arden, B. Hauber, F.R. Johnson, D. Watson, P. Mavros, J. Pellisier, P. Peloso, S. Sen, A.F. Mohamed, and J.M. Gonzalez. Physicians’ Stated Preferences Over Benefits and Risks Associated With NSAID Use in Patients With Osteoarthritis in UK.

Mladsi, D., S. Earnshaw, N. Akashi-Ronquest, and M. Keith. Proposed Methods for Conducting Sensitivity Analyses on Threshold-Derived Estimates of Value-Based Price and Product Profi les of Early Stage Drugs.

Mladsi, D.. Review of Utility Estimates in Atopic Dermatitis.

Beard, S.M., T.K. Le, Y. Zhao, and N. Roskell. The Cost-effectiveness of Duloxetine in the Treatment of Fibromyalgia in the United States.

Meyers, J., D. Mitra, J. Doan, and C. Leeflang. The Role of Patient Selection Criteria in Identifying Ovarian Cancer Patients in a Retrospective Database Analysis.

Mladsi, D., S. Earnshaw, N.A. Ronquest, and M. Keith. Threshold Pricing Model: Not Just Another Cost-effectiveness Model.

Rinaldi, F., S. Hwang, D. Strutton, S. Earnshaw, and R. Farkouh. Clinical and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccination In Singapore and Hong Kong.

Talbird, S.E., K. Bell, J.B. Graham, L. Deal, and J. Mauskopf. Cost-effectiveness Analysis for Treatment of Symptomatic Uterine Fibroids Among Premenopausal Women Seeking to Retain Their Uterus.

Jackson, D., S. Earnshaw, R.A. Farkouh, and L.H. Schwamm. Cost-effectiveness of Perfusion Imaging With Computed Tomography to Identify Patients for Intravenous Thrombolysis: A Hospital Perspective.

Earnshaw, S., M. Pignone, A.M. Fendrick, and J. Scheiman. Cost-effectiveness of Proton Pump Inhibitors for Prevention of Gastrointestinal Adverse Events When Using Aspirin for Primary Cardiovascular Prevention.

Colosia, A.D., S.B. Khan, G. Peltz, G. Pohl, E. Liu, and J.A. Kaye. ELECTRONIC MEDICAL RECORDS: QUALITY CANCER CARE AND COST-EFFECTIVENESS.

West, N., M. Leung, M. Halpern, and E.C. Faulkner. Evidence Used During Pharmaceutical Technology Assessment.

Hauber, B., A.F. Mohamed, and M.P. Neary. How Much Do Patients with Renal Cell Carcinoma (RCC) Value Progression-free Survival ABSTRACT 27007 in Medical Decision Making—Results from a Benefit-Risk Conjoint Study.

Davis, K.L., D. Mitra, C. Leteneux, B. Bapat, and C. Naujoks. Medical Service Utilization and Costs by Disease Severity, Sustained Viral Response, and Genotype in European Patients with Chronic Hepatitis C Virus.

Johnson, F.R., B. Hauber, J. Gonzalez, B. Levitan, and P. Coplan. Patient Preference Weights for Benefi t-Risk Analysis: A Statin Case Study.

Mordin, M., S.E. Lewis, A. Gnanasakthy, C. Demuro-Mercon, K. Copley-Merriman, and S. Fehnel. Patient-Reported Outcomes as Mentioned in Product Development Guidance.

Ervin, C.M., S. Fehnel, R. Carson, C. Kurtz, S. Shiff, and J. Johnston. Selecting Chronic Constipation (CC) Clinical Trial Endpoints: Incorporating the Patient’s Voice.

Bapat, B., K.L. Davis, K. Bell, L. Deal, and S.E. Talbird. Treatment Patterns and Economic Burden of Uterine Fibroids in a United States Managed Care Database.

Davis, K.L., D. Mitra, C. Leteneux, B. Bapat, and C. Naujoks. Utilization and Cost of Peginterferon Plus Ribavirin Combination Therapy in the Management of Chronic Hepatitis C Virus in Europe.

Gilsenan, A., E.B. Andrews, B. Calingaert, D.A. Crozier, and A. Vanderpuije. Evaluation of Current Risk Evaluation and Mitigation Strategies.

Tennis, P., A. Zavras, C. Laskarides, and H. Tan. Predictive Value of ICD and CPT Codes for Identifying Osteonecrosis of the Jaw.

Gilsenan, A., R.H. Stanford, C. Bui, R.M. Ziemiecki, and H. Ortega. Predictors of Uncontrolled Asthma in Adult and Pediatric Patients: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS).

Midkiff, K., A. Gilsenan, R. Martin, Y. Wu, D. Masica, and E.B. Andrews. The Impact of Patient Access Pathways on Postmarketing Drug Safety Studies Using Cancer Registry Data.

Varas-Lorenzo, C., C. Johannes, L. McQuay, K. Midkiff, M.R. Stang, and D. Fife. Validation of Serious Ventricular Arrhythmias in an Adminisrative Database.

Blum, J., S. Hu, D.M. Odom, B. Sherrill, and S. Gluck. Effect of Age on Overall Survival in Capecitabine - treated Patients with Metastatic Breast Cancer.

Sherrill, B., Y. Wu, M. Amonkar, M. Arbushites, and A. Di Leo. First-Line Treatment With Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for Patients with ErbB2+ (HER2+) Metastatic Breast Cancer: Quality of Life Analyses Using Repeated Measures and Pattern Mixture Models.

Sherif, B.N., B. Sherrill, M. Amonkar, Y. Wu, J. Maltzman, L. O'Rourke, and S. Johnston. Lapatinib Plus Letrozole Compared With Letrozole Alone as First-Line Therapy in Hormone Receptor Positive HER2+ Metastatic Breast Cancer: A Quality of Life Analysis.

Gluck, S., C. Russell, J. O'Shaughnessy, G. Yuan, D.M. Odom, B. Sherrill, and J. Blum. Relationship Between Survival and Estrogen Receptor Status in Patients With Metastatic Breast Cancer Treated With Capecitabine and Docetaxel: An Exploratory Data Analysis.

Sherrill, B., B.N. Sherif, M. Amonkar, Y. Wu, J. Maltzman, L. O'Rourke, and S. Johnston. Quality of Life and Quality-Adjusted Survival (Q-TWiST) in Patients Receiving Lapatinib Plus Letrozole as First-Line Therapy in Hormone Receptor Positive, HER2+ Metastatic Breast Cancer.

Faulkner, E.C.. The Evolution of Personalized Medicine: The Role of Pharmacogenomics in Managed Care.

Sherrill, B., M. Amonkar, B. Sherif, J. Maltzman, L. O'Rourke, and S. Johnston. An Exploration of the Association of QOL Scores With Tumor Progression Status in First-Line HR+, HER2+ MBC Patients Treated With Lapatinib Plus Letrozole or Letrozole Alone.

Tennis, P., E. Andrews, C. Ambrose, S. Toback, and M.D. Rousculp. A Postmarketing Commitment to Evaluate the Frequency of Use and Safety of Live Attenuated Influenza Vaccine Use in Non-Recommended Populations Less Than 59 Months of Age.

Johnson, F.R.. Patient and Physician Benefit-Risk Preferences: Evidence From 7 Studies.

Johnson, F.R.. Stated Benefit-Risk Tradeoff Preferences From Conjoint Analysis.

Knight, C., A. Colligs, and J. Lipinski. A Budget Impact Analysis of Dienogest in Treating Endometriosis-Associated Pelvic Pain in Germany.

Lloyd, A., J.F.P. Bridges, and F.R. Johnson. Classifying patient reported outcomes: Developments in the field suggest a new taxonomy.

Brogan, A., S. Soorapanth, V. Donatz, A. Hill, and E. Smets. Comparative Cost-Efficacy Analysis of Darunavir/r and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in Germany.

Earnshaw, S., C.L. McDade, L. Black, and M. Kattan. Cost-effectiveness of Chemoprevention With Dutasteride Based on Results From the REDUCE Clinical Trial.

Farkouh, R., M. Wilson, M.L. Tarrants, J. Castelli-Haley, and C. Armand. Cost-effectiveness of Rasagiline Compared With Other First-Line Treatment Options for Early Parkinson’s Disease in the United States.

Wolowacz, S., M. Jhaveri, and K. Tangirala. Cost-Utility Model to Evaluate Adjuvant Chemotherapy for Early Breast Cancer in the United States.

Mauskopf, J., J.B. Graham, J. Bae, and C. Gaich. Impact of Including Prasugrel on the Formulary for Patients Who Undergo Percutaneous Coronary Intervention for Acute Coronary Syndrome.

de Cambra, S., D. Mladsi, and S. Neale. International Payer Research: Comparing and Contrasting Payer Roles and Research Methods in Canada, Spain, and the UK.

Mladsi, D., S. de Cambra, A. Gilabert-Perramon, and E.C. Faulkner. Orphan Drug Funding: A Model for Personalized Medicine?.

de Cambra, S., D. Mladsi, S. Neale, and E.C. Faulkner. Reimbursement of Active Immunotherapeutics: An Analysis Based On a Study of Current Reimbursement Approaches.

Zimovetz, E., and S. Wolowacz. Reviewer’s Checklist for Assessing the Quality of Decision Models.

Kauf, T., K.L. Davis, S. Earnshaw, E.A. Davis, and M.E. Watson. SPILLOVER ADHERENCE EFFECTS OF FIXED-DOSE COMBINATION HIV THERAPY.

Wolowacz, S., M. Samuel, V.K. Brennan, J. Jasso-Mosqueda, and I. van Gelder. The Cost of Illness of Atrial Fibrillation: A Systematic Review.

Faulkner, E.C.. The Devil is in the Details: International Comparison of Technology Assessment Processes and Payer Uptake of Personalized Medicine and Implications for the Field.

Wolowacz, S.. The United Kingdom’s National Institute for Health and Clinical Excellence: NEW DEVELOPMENTS.

Mauskopf, J., C. Schmitt, K.S. Boye, P.L. McCollam, M.D. Juniper, and J.A. Birt. Adherence to Guidelines for Sensitivity Analysis: Cost-Effectiveness Analyses of Dual Oral Antiplatelet therapy.

Juniper, M.D., C. Gaich, R. Frear, and B. Sweet. Adhering to Multiple Guidelines for Preparation of Formulary Submission Dossiers: Aligning with Payer Expectations.

Soorapanth, S., A. Brogan, J. Mrus, and E. Smets. Comparative Cost-Efficacy Analysis of Darunavir/r for First-Line Treatment of HIV Infection in the United States.

Wolowacz, S.E., N.S. Roskell, J.M. Plumb, A. Clemens, P. Robinson, G. Dolan, and I.J. Brenkel. Cost-effectiveness of Dabigatran Etexilate 150mg for the Prevention of Venous Thromboembolism in Patients Aged Over 75 Years Undergoing Total Hip or Knee Arthroplasty.

Wolowacz, S.E., N.S. Roskell, J.M. Plumb, A. Clemens, P. Robinson, G. Dolan, and I.J. Brenkel. Cost-effectiveness of Dabigatran Etexilate 150mg for the Prevention of Venous Thromboembolism in Patients Undergoing Total hip or Knee Arthroplasty with Moderate Impairment of Renal Function.

Farkouh, R.A., M.R. Wilson, M. Tarrants, J. Castelli-Haley, and C. Armand. Cost-Effectiveness of Rasagiline Versus Ropinirole Extended Release in Delaying Levodopa in the Treatment of Early Parkinson's Disease in the United States.

Nelson, L.M., L.D. Mcleod, L.J. Lee, C.D. Hill, and C.T. Sweeney. Effects of Insulin Therapy on the Diabetes Symptom Checklist-Revised (DSC-R): Data from a Large Insulin Clinical Trial.

Mordin, M.M., M. Clark, C.A. Siersma, K. Copley-Merriman, and A. Gnanasakthy. Impact Of The FDA Draft Guidance on Patient Reported Outcomes (PRO) Label Claims for Approved Drug Products in the US: Has It Made a Difference?.

Gilligan, T.M., and C.M. Hill. Longitudinal Data Exploration With Stacked Cumulative Percent Plots for Categorical Data.

Mohamed, A.F., A.B. Hauber, J. Medjedovic, and C. Beam. Patient Preferences and Stated Adherence for Hepatitis C Virus Treatments.

Copley-Merriman, K., S.M. Barrows, J. Whiteley, and A.M. Barrett. Value Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool.

Sherrill, B., M. Amonkar, B.N. Sherif, J. Maltzman, L. O'Rourke, and S. Johnston. A Q-TWiST Analysis of Lapatinib Plus Letrozole Compared With Letrozole Alone as First-Line Therapy in Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC).

Goldberg, J.F., L.D. Mcleod, S.E. Fehnel, L.R. Hamm, and K. Gilchrist. Development and Evaluation of a New Patient-Reported Instrument: the Bipolar Functional Status Questionnaire.

Burstein, H., K.M. Blackwell, Y. Wu, A. Storniolo, H. Rugo, M. Amonkar, C.S. Ellis, G. Sledge, J. Baselga, and J. O'Shaughnessy. Impact of Lapatinib Plus Trastuzumab Versus Single-Agent Lapatinib on Quality of Life of Patients With Trastuzumab-Refractory HER2+ (ErbB2+) Metastatic Breast Cancer.

Sherrill, B., A. Di Leo, M. Amonkar, M. Koehler, and M. Arbushites. A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis Comparing First-Line Therapy With Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for Patients With HER2+ Metastatic Breast Cancer (MBC).

Kaufman, B., T. Bachelot, Y. Wu, M. Amonkar, t. zaks, V. Salazar, P. Viens, and S. Johnston. Lapatinib Monotherapy in HER2+ Relapsed or Refractory Infl ammatory Breast Cancer (IBC): Quality of Life (QOL) Assessment.

Rugo, H., P. Kaufman, M.U. Yood, A. Brufsky, M. Mayer, E. Tan-Chlu, D. Yardley, M. Birkner, L. Wang, M. Brammer, and D. Tripathy. registHER: An Observational Cohort Study of Survival of Patients with HER2-Positive Metastatic Breast Cancer and Use of Trastuzumab Following Progression.

Wu, Y., H. Burstein, K.M. Blackwell, A. Storniolo, H. Rugo, M. Amonkar, C.S. Ellis, G. Sledge, J. Baselga, and J. O'Shaughnessy. Lapatinib Plus Trastuzumab Versus Lapatinib Monotherapy in Trastuzumab-Refractory ErbB2+ Metastatic Breast Cancer Patients: Quality of Life Assessment.

Zhou, X., D. Cella, A. Segreti, D. Cella, D. Cameron, C. Geyer, M. Amonkar, S. Stein, and M. Walker. Effect of Lapatinib Plus Capecitabine on Quality of Life Compared to Capecitabine Alone in ErbB2-Positive Metastatic Breast Cancer: An Exploratory Analysis.

Sherrill, B., M.M. Amonkar, Y. Wu, C. Hirst, S.H. Stein, M.D. Walker, and J. Cuzick. Disease Progression as a Predictor of Overall Survival in Metastatic Breast Cancer: A Meta-analysis.

Zhou, X., A. Segreti, D. Cella, D. Cameron, C. Geyer, M.M. Amonkar, S.H. Stein, and M.D. Walker. Lapatinib + Capecitabine vs. Capecitabine alone for ErbB2+ Metastatic Breast Cancer: Quality-of-Life Assessment.

Zhou, X., A. Segreti, D. Cella, D. Cameron, C. Geyer, M.M. Amonkar, S.H. Stein, and M.D. Walker. Lapatinib Plus Capecitabine Versus Capecitabine Alone for ErbB2-Positive Metastatic Breast Cancer: Quality-of-Life Assessment.

Wu, Y., A. Segreti, D. Cella, A. DiLeo, M.M. Amonkar, M. Koehler, M. Arbushites, and M.D. Walker. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for First-Line Metastatic Breast Cancer in ErbB2-Positive Patients: Quality-of-Life Results.

Perez-Gutthann, S.. Lessons Learned from Epidemiologic Studies and Clinical Trials.

Gilsenan, A.W., A. Ladner, C. Varas-Lorenzo, T. Kold Olesen, C. Karup, and E.B. Andrews. Incidence of Cardiovascular and Cerebrovascular Events Among Men With Prostate Cancer.

DeStefano, F., C.D. Heath, D.B. Currivan, and S.F. Wetterhall. Influenza Vaccination Among Adults in Four North Carolina Counties, 2007–2008.

Midkiff, K., C.B. Johannes, and A.K. Mohan. Utility of Multiple Databases in a Surveillance Program for Prescription Narcotic Analgesics.

Knight, C.J.. A Systematic Review of the Efficacy of Recombinant Activated Factor VII and Activated Prothrombin Complex Concentrate in the On-Demand Treatment of Minor to Moderate Bleeding Episodes for Haemophilia Patients With Inhibitors.

Odom, D., G. Devercelli, L. Bennett, M. Peeters, M. Wolf, and R. Amado. Health-Related Quality of Life (HRQOL) and Colorectal Cancer (CRC) Symptoms in Metastatic CRC: Panitumumab Plus Best Supportive Care (BSC) Versus BSC Alone by KRAS Tumor Status.

Mitra, D., and S.D. Candrilli. Inpatient Costs and Outcomes Associated With Hepatitis C, Human Immunodefi ciency Virus, and Co-Infection With Both in the United States.

Brennan, V.K., and S.E. Wolowacz. A Systematic Review of Breast Cancer Utility Weights.

Barrett, A.M., A.D. Colosia, K.S. Boye, and O. Oyelowo. Burden of Obesity: 10-Year Review of the Literature on Costs in Nine Countries.

Barrett, A.M., K.S. Boye, and O. Oyelowo. Burden of Obesity: 10-Year Review of the Literature on Obesity Prevalence in Nine Countries.

Davis, K.L., D. Mitra, J. Medjedovic, C. Beam, and V.K. Rustgi. Direct Economic Burden of Chronic Hepatitis C Virus in a Large Managed Care Population.

Davis, K.L., D. Mitra, and S. Kotapati. Direct Economic Burden of High-Risk and Metastatic Melanoma: Evidence From the SEER-Medicare Linked Database.

Mitra, D., K.L. Davis, J. Medjedovic, C. Beam, and V.K. Rustgi. Health Care Utilization and Costs Associated with Chronic Hepatitis C in a Managed Care Population.

Mitra, D., S. Candrilli, K.L. Davis, and B. Bapat. Inpatient Costs and Outcomes Associated With Chronic Hepatitis C-Related Complications in the United States.

Copley-Merriman, C., S.E. Fehnel, J. Chandler, and D. Wild. Obtaining a Patient-Reported Outcomes Label Claim: What Evidence Do You Need?.

Kotapati, S., D. Mitra, K.L. Davis, and U. Iloeje. Predictors of Treatment Choice in High-Risk and Metastatic Melanoma: Evidence From Linked Electronic Medical Records and Administrative Claims Data.

Mohamed, A.F., F.R. Johnson, A.B. Hauber, D. Meddis, and S. Wagner. Preferences for Onset of Effect of Combination Maintenance Medication Among Asthma Patients.

Hauber, A.B., A.F. Mohamed, F.R. Johnson, H. Falvey, and E. Snyder. Preferences for Oral Antidiabetic Agents Among People With Type 2 Diabetes.

Mitra, D., K.L. Davis, S. Kotapati, and U. Iloeje. Real-World Treatment Patterns in High-Risk and Metastatic Melanoma: Evidence From the SEER-Medicare Linked Database.

Candrilli, S., R. Balkrishnan, and S.H. O'Brien. The Effect of Injury Severity on the Incidence and Resource Utilization-Related Outcomes of Deep Vein Thrombosis Among Pediatric Trauma Admissions in the United States.

DiBenedetti, D., and C.D. Hill. Adherence Among Patients with Parkinson’s Disease Taking Ropinirole Immediate Release At Least Three Times Daily.

DiBenedetti, D., J.A. Sollano, and R.L. Kolotkin. The Impact of Being Overweight on Health-Related Quality of Life in Type 2 Diabetic Patients: Patient Interviews.

Sherrill, B., C. Hirst, Y. Wu, M.M. Amonkar, and S.H. Stein. Retrospective Pooled Analysis to Assess Correlation Between Time to Progression and Overall Survival in Patients With Breast Cancer.

Mauskopf, J., A.J. Brogan, C. Malmberg, and P. Hwang. Cost-Effectiveness of Darunavir for the Management of HIV-Infected, Treatment-Experienced Adults in Canada.

Sherrill, B., A.A. Allshouse, and S.H. Stein. Lapatinib Plus Capecitabine Versus Capecitabine Alone for Metastatic Breast Cancer: Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST).

Sherrill, B.H., A.A. Allshouse, M.M. Amonkar, and S.H. Stein. Lapatinib plus capecitabine versus capecitabine alone for metastatic breast cancer: Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST).

Graham, C.N., S.R. Earnshaw, and M. Saunders. Assessing the Impact of Smoking Cessation Therapies on a Managed Care Organization's Budget Using Census Region and State-Specific Smoking Estimates.

Earnshaw, S.R., V. Sikirica, N.S. Roskell, P.R. Shannon, S. Beard, J. Schein, D. Doshi, and C. Janagap. Economic Analysis of Short-Course Levofloxacin Versus Amoxicillin/Clavulanate in Treating Acute Bacterial Exacerbations of Chronic Bronchitis.

Davis, K.L., S.D. Candrilli, and H.M. Edin. Prevalence and Cost Impact of Nonadherence with Antiepilepsy Drugs Among Adults in a Managed Care Population.

Candrilli, S.D., E. Lee, S.S.K. Tang, S. Bassin, H.J. Laird, S.S. Levy, and N.D. Wong. Cardiovascular Risk in US Urban Hispanic Populations: Regional Data From Community Outreach Programs.

Tang, S.S.K., E. Lee, S.D. Candrilli, H.J. Laird, S.S. Levy, S. Bassin, and N.D. Wong. Prevalence, Treatment, and Control of Hypertension and/or Dyslipidemia Among Hispanic Adults in US Communities.

Lee, E., S.S.K. Tang, S.D. Candrilli, S. Bassin, H.J. Laird, S.S. Levy, and N.D. Wong. Regional Differences in the Prevalence of Hypertension and Dyslipidemia in US Urban Hispanic Populations.

Hirst, C., and E. Andrews. International Therapeutic Risk Management.

Sherrill, B., A.A. Allshouse, M.M. Amonkar, M.D. Walker, and S.H. Stein. A Comparison of Lapatinib Plus Capecitabine Versus Capecitabine Alone for Quality-Adjusted Survival in Metastatic Breast Cancer: a Q-TWiST Analysis.

Beard, S.. Developing Health Economic Models for Submission to Health Authorities as Evidence of Product Value.

Midkiff, K., A. Gilsenan, R. Martin, D.N. Masica, and E. Andrews. Characteristics of Patients in a Postmarketing Osteosarcoma Surveillance Study.

Wang, J., B. Sherrill, and W. Irish. Determining Sample Size For Postmarketing Surveillance of Rare Adverse Events.

Gilsenan, A.W., K. Midkiff, Y. Wu, R. Martin, D.N. Masica, and E. Andrews. Factors Associated With Interview Completion Rates in a Surveillance Study of Osteosarcoma and Antecedent Exposures.

Perez-Gutthann, S.. Risk Management Planning: An industry viewpoint – Achievement and Problems.

Midkiff, K., C.B. Johannes, and A.K. Mohan. Strengths and Limitations of Drug Abuse Warning Network Data Used in a Surveillance Study.

Devine, S.T., S. West, E. Andrews, P. Tennis, S. Eaton, J. Thorp, and A. Olshan. The Identification of Pregnancies Within The Full Feature-General Practice Research Database.

Devine, S.T., S. West, E. Andrews, P. Tennis, S. Eaton, J. Thorp, and A. Olshan. The Validation of Neural Tube Defects in the General Practice Research Database.

Johnson, F.R., A.B. Hauber, A.F. Mohamed, C. Leibman, H.M. Arrighi, A.S. Zbrozek, and P. Coplan. Alzheimer’s Disease Progression Healthy-Year Equivalents: Stated Risk-benefit Trade-off Preferences.

Zyczynski, T.M., S.M. Beard, S.R. Earnshaw, and C.L. McDade. Cost-effectiveness Analysis of the Use of Iodixanol Compared to Iohexol in the United Kingdom.

Graham, J.B., S.R. Earnshaw, J. Castelli-Haley, M. Oleen-Burkey, and K.P. Johnson. Cost-effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis in the Presence of Long-Term Clinical Evidence.

Leeuwenkamp, O., R. Morlock, C. Bell, A.J. Brogan, and J. Mauskopf. Costs and Outcomes of Atypical Antipsychotics for the Treatment of Acute Schizophrenia.

Mohamed, A.F., A.B. Hauber, F.R. Johnson, M.E. Watson, and J.E. Hernandez. Incorporating Probabilistic Attributes in a Stated-Choice Risk-Benefit Survey.

Mitra, D., K.L. Davis, S.D. Candrilli, B.J. Tortella, and A.V. Joshi. Inpatient Costs and Outcomes Associated With Pediatric Traumatic Injury in the United States by Injury Severity and Trauma Center Designation.

Sherrill, B.H., C. Hirst, M.M. Amonkar, and S.H. Stein. Correlation Between Time to Progression and Overall Survival in Patients With Metastatic Breast Cancer.

Mauskopf, J., A.J. Brogan, C. Malmberg, and P. Hwang. Cost-Effectiveness of Darunavir for the Management of HIV-Infected, Treatment-Experienced Adults in Canada.

Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage over a Two-Year Managed Care Enrollment Period.

Mitra, D., K.L. Davis, and R. Baran. Health Care Utilization and Costs Associated With Constipation (C-ONLY) and Co-Occurring Irritable Bowel Syndrome and Constipation (IBS+C) Compared to Migraine in a Large Managed Care Population.

Ozdemir, S., A.F. Mohamed, G. Huiber, and F.R. Johnson. How Good Is Good Enough? Internal Validity of Stated Preferences for Drug Therapies.

Candrilli, S., K.L. Davis, D. Mitra, B.J. Tortella, and A.V. Joshi. Inpatient Costs and Outcomes Associated With Traumatic Injury in the United States by Injury Severity and Trauma Center Designation.

Mcleod, L.D., S.E. Fehnel, L.J. Zografos, S.D. Sander, T.G. Curtis, and H. Shah. The Impact of Restless Legs Syndrome on Various Dimensions of Life: Results of a Web-Based Patient Survey.

Perez-Gutthann, S.. Evaluación de Señales de Alerta en el contexto global de la Gestión de Riesgos.

Davis, K.L., S.D. Candrilli, A.V. Joshi, and B.J. Tortella. The Direct Economic Burden of Blunt and Penetrating Trauma Among the Elderly Population.

Perez-Gutthann, S.. What Have We Learned from Safety Cases for New Drug Development? Industry Responding to Learning from Safety Cases.

Davis, K.L., J.K. Allen, J. Kirsch, K.H. Davis, and H.M. Edin. The Prevalence of Treatment Non-Adherence Among Patients with Parkinson's Disease in a United States Managed Care Population.

Williams, R.E., D. DiBenedetti, X. Zhou, S.E. Fehnel, and R.V. Clark. Healthcare Seeking Behavior Among Peri- and Post-Menopausal Women: Results from the US Population-Based MEPI Study.

Williams, R.E., D. DiBenedetti, X. Zhou, S.E. Fehnel, and R.V. Clark. The Menopause Epidemiology (MEPI) Study: Vasomotor Symptom Results from a Large Population-Based Study.

Earnshaw, S.R., A.V. Joshi, M.R. Wilson, and J. Rosand. Cost-effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage.

Earnshaw, S.R., S.M. Beard, N.O. Lynch, A. Cooper, W. Cowell, and H. Middelhoven. A Comparison of the Cost-Effectiveness of Bisphosphonates Using Persistence Data from a UK Propsective RCT.

Candrilli, S., and J. Mackell. Effect of NCEP ATP III Guideline Revisions on the Prevalence of Dyslipidemia Among the Elderly: Evidence from NHANES.

Earnshaw, S.R., A.V. Joshi, and M.R. Wilson. Cost-effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage: A US Managed Care Perspective.

Earnshaw, S.R., and J. Gricar. Good Practices for High Quality Decision Analytic Models.

Davis, K.L., J. Mauskopf, W. Chow, J. Chao, and B. Seal. Titration and persistence with tamsulosin among men with benign prostatic hyperplasia in a large managed care population.

Graham, C.N., S.R. Earnshaw, D.G. Smith, S. Hogue, J. Gitchell, H. Marsh, W. Becker, and M. Saunders. Assessing the Impact of Smoking Cessation Therapies on a Managed Care Organization's Budget.

Davis, K.L., A.V. Joshi, B.J. Tortella, and S.D. Candrilli. The Direct Economic Burden of Blunt and Penetrating Trauma in a Managed Care Population.

Rubino, A., D. Mines, N.S. Roskell, P. Tennis, E. Andrews, and S. Welch. Risk of Suicide During Venlafaxine Treatment Compared with Citalopram, Fluoxetine, and Dothiepin Treatment: A Population-based Analysis in the United Kingdom.

Ozdemir, S., F.R. Johnson, C. Mansfield, S. Hass, and J. White. Are Crohn’s Parents More Risk Averse Than Adult Patients? Acceptable Tradeoffs between Efficacy and Adverse-Event Risks.

Johnson, F.R., and G.L. Van Houtven. Evaluating Risk-Benefit Tradeoffs and Health-Related Utility: A Comparison of Standard Gamble and Conjoint Methods.

Johnson, F.R., S. Ozdemir, A.F. Mohamed, D. Marshall, and K. Philips. How Does price Matter in Healthcare Stated-Choice Surveys?.

Zlateva, G.P., J.C. Javitt, S.R. Earnshaw, A.M. Pliel, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-effectiveness Model for Age-related macular Degeneration: Comparing Early and Late Macugen Treatment.

Earnshaw, S.R., S.M. Beard, N.O. Lynch, and W. Cowell. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK.

Mladsi, D.M.. Developing Health Economic Models for Assessing Cost-Effectiveness and Product Value.

Kauf, T.L., M.S. Saag, M. Kitahata, B. Gazzard, S.R. Earnshaw, C.N. Graham, E.A. Davis, A. Shearer, and J. Mauskopf. Simulation Modeling of Adherence and Resistance on Long-Term Outcomes in HIV.

Varas-Lorenzo, C., L. McQuay, S. Eaton, I. Saez-Lloret, M. Melero-Montes, D. Miller, and S. Perez-Gutthann. Characterization of US Adult Users of Antihypertensive Medications.

Gilsenan, A., X. Zhou, F. Coste, and A.A. Allshouse. Comparison of Data from a US National Survey (NHANES) with Data from a Cohort Recruited from the Internet.

Sanchez Matienzo, D., L.L. Lanza, L.J. Mcquay, L. Gutierrez, and S. Perez-Gutthann. Descriptive Study of Users of Depo-Medroxyprogesterone Acetate (DMPA) in the MHRA GPRD.

Nyberg, F., S. Hada, and K.J. Rothman. Iressa and Interstitial Lung Disease (ILD) in Japan - Lessons from a Large Nested Case-Control Study to Evaluate a Safety Issue.

Johnson, F.R., S. Ozdemir, E. Andrews, S. Hass, D.P. Miller, J. White, C. Siegel, and B. Sands. Patients' Willingness to Accept Risk-Benefit Tradeoffs in Treating Crohn's Disease.

Rubino, A., L. McQuay, M. Kvasz, and P. Tennis. Population-Based Study of Time to Insulin After Failure of Oral Antidiabetic Therapy in Type 2 Diabetes in the UK.

Lanza, L.L., L. Wang, T. Simon, and W. Irish. Risk of Selected Outcomes After Solid Organ Transplantation: A Literature Review.

Rubino, A., S.J. Evans, and L. Smeeth. Risk of Stroke During Treatment with Atypical and Conventional Antipsychotics: A Population-Based Study in the United Kingdom.

Rubino, A., N.S. Roskell, P. Tennis, D. Mines, S. Weich, and E. Andrews. Risk of Suicide During Venlafaxine and Comparator Antidepressants Treatment.

Wang, J., A.A. Allshouse, and W. Irish. Underestimation of Variance Due to Using Simple Random Sampling Statistical Methods Applied to Data Obtained from a Cluster Sampling Design.

Bell, C.F., J.B. Graham, S.R. Earnshaw, M. Oleen-Burkey, J. Castelli-Haley, and K. Johnson. Assessing the Cost-Effectiveness of Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis Based on Long-Term Data.

Candrilli, S.D., and J.A. Mauskopf. How Much Does a Day in the Hospital Cost?.

Kolotikin, R.L., R. Crosby, C. Radigue, and A.A. Allshouse. Impact of Abdominal Obesity on Health-Related Quality of Life.

Mauskopf, J.A., G.S. Simon, C. Nimsch, and A.A. Krishnan. Measurement of Utility Losses in Depression.

Bala, M.V., J.A. Mauskopf, and G.A. Zarkin. Presenting Uncertainty Around Cost-Effectiveness Estimates to Decision Makers: How Sure Are We?.

Johnson, F.R., and G.L. Van Houtven. Quantifying Patients' Risk-Benefit Tradeoff Preferences: A Conceptual and Empirical Comparison of Methods.

Earnshaw, S.R., C.N. Graham, M.M. Amonkar, and C. Barr. The Cost-Effectiveness of Ibandronate in the Treatment of Postmenopausal Osteoporosis in the US.

McCrink, L., S.M. Beard, and T. Le. The Relationship Between Health-Related Quality of Life (HRQOL) and Pain Response in Patients with Diabetic Peripheral Neuropathic Pain.

Johnson, F.R., S. Ozdemir, C.A. Mansfield, B. Sands, C. Siegel, S. Hass, D. Miller, and J. White. Weighing Treatment Benefits Against Treatment Risks: Crohn’s Disease Patients’ Willingness to Accept Risk-Benefit Tradeoffs.

Mladsi, D.M., and A.M. Barrett. Winners and Losers: Patterns in Economic Evaluations of Anti-Epileptic Drugs.

Johnson, F.R., S. Ozdemir, C.A. Mansfield, S. Hass, and J. White. Are Adults More Averse to Treatment Risks for Their Children Than They Are for Themselves?.

Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. Budgetary Impact Analysis of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage: A US Health Plan Perspective.

Hauber, B., F.R. Johnson, and S. Ozdemir. Conjoint Analysis QALYs for Acute Conditions: An Application to Vasomotor Symptoms.

Javitt, J.C., S.E. Wolowacz, N.S. Roskell, F. Maciver, S. Kelly, A.M. Pleil, and G.P. Zlateva. Cost-Effectiveness of Pegaptanib in Age-Related Macular Degeneration: The Impact of Differences Between USA and UK Health Care Systems.

Wolowacz, S.E., N.S. Roskell, F. Maciver, and S. Kelly. Cost-Utility Analysis for Pegaptanib in Age-Related Macular Degeneration in the UK: The Impact of Demographic and Disease Characteristics.

Candrilli, S.D., K.L. Davis, A.V. Joshi, and B.J. Tortella. Healthcare Utilization and Costs Associated with Blunt and Penetrating Trauma in a United States Managed Care Population.

Zhou, X., C. Radigue, A.A. Allshouse, and A. Gilsenan. In Europe, How Representative are Overweight/Obese Subjects Recruited Via the Internet?.

Wolowacz, S.E.. The National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) Process: An Update on the First Round of Submissions.

Earnshaw, S.R., Y. Moride, A. Moshyk, and S. Rochon. Cost-effectiveness of Macugen Compared to Photodynamic Therapy (PDT) with Verteporfin and Standard Care in the Treatment of Subfoveal Wet Age-Related Macular Degeneration (AMD) in the Elderly in Canada.

Schnitzler, M.A., S.R. Earnshaw, C.N. Graham, W.D. Irish, and R. Sato. Lifetime Cost-Effectiveness of Calcineruin Inhibitor-Free Immunosuppressive Treatment After De Novo Renal Transplantation.

Williams, V., R. Morlock, S. Fehnel, M.M. Wills, C.D. Hill, S. Barrows, J. Cappelleri, and D. Feltner. Development and Evaluation of the Daily Assessment of Symptoms–Anxiety (DAS-A) Scale for Measurement of Onset of Symptom Relief in Patients with GAD.

Fehnel, S., L.D. Mcleod, H.M. Edin, and S.L. Hogue. Psychometric Evaluation of the Motivation and Energy Inventory –Short Form (MEI-SF).

Mcleod, L.D., S.E. Fehnel, M.M. Wills, L.R. Hamm, and K. Gilchrist. Psychometric Validation of a Patient-Reported Instrument Assessing Functional Status in Bipolar Disorder.

Britt, D.M., S.E. Fehnel, A.L. Granger, X. Zhou, and R. Williams. Quality of Life and the Prevalence of Vasomotor Symptoms in a Population-Based Sample of Peri- and Post-Menopausal Women.

Ettinger, B., A.J. Brogan, C.N. Graham, M.M. Amonkar, and R. Baran. Modeled cost impact of persistence with bisphosphonate therapy for women with postmenopausal osteoporosis.

Irish, W., J. Wang, B. Sherrill, K. Lentine, T. Burroughs, and M. Schnitzler. An Econometric Evaluation of All-Cause Graft Failure: A Population-Based Approach An Econometric Evaluation of All-Cause Graft Failure: A Population-Based Approach.

Earnshaw, S.R., A.J. Brogan, C.N. Graham, M.M. Amonkar, R. Baran, and A. Hebborn. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis.

Johnson, F.R., S. Ozdemir, and B. Hauber. Is Relief Worth the Risk? Risk-Benefit Preferences for Treatments for Menopause Symptoms.

Johnson, F.R., S. Ozdemir, and A.B. Hauber. Stated or Misstated Health Preferences? Statistical Consequences of Suboptimal Experimental Design in Conjoint Surveys.

Earnshaw, S.R., P.A. Pankaj, S.D. Candrilli, J. DePlatchett, C.N. Graham, and L. Williams. 17th Annual Meeting & Showcase.

Gilsenan, A., P. Tennis, E.A. Andrews, X. Zhou, F. Coste, and C. Radigue. Is It Feasible to Conduct a Cohort Study via the Internet?.

Gilsenan, A.W., E.B. Andrews, A.N. Burdett, and R. Martin. Post-Marketing Safety Surveillance Studies Requiring Access to Patients and Charts: Does Persistence Yield Results?.

Burdett, A.N., C. Gard, A. Gilsenan, Z. Hirji, J. Raskin, and D. Miller. Prevalence and Costs Associated with Treating Depression with Painful Physical Symptoms in a Canadian Administrative Services Database.

Gilsenan, A., X. Zhou, P. Tennis, E.A. Andrews, F. Coste, and C. Radigue. Should We Believe Results Obtained from an Internet-Based Cohort Study?.

Candrilli, S.D., M.A. Lucero, K. Davis, H. Kan, and M. Covington. Burden of Illness Associated with Symptoms of Diabetic Peripheral Neuropathy and Diabetic Retinopathy.

Tafesse, E., A. Claxton, A.L. Granger, J. Sanders, D. Apelian, E. Atillasoy, and U. Iloeje. Estimates of Health Care Costs For Lamivudine-Refractory Chronic Hepatitis B (CHB) Patients.

Davis, K., S.D. Candrilli, H. Kan, M.A. Lucero, and M. Covington. Estimating the Effects of Diabetic Peripheral Neuropathy and Diabetic Retinopathy on Quality-of-Life Using Data from the 2001-2002 National Health and Nutrition Examination Survey.

Johnson, F.R., and S. Ozdemir. Bipolar Patients' Stated Therapy Preferences and Likely Adherence.

Johnson, F.R.. Conjoint Analysis: Application to Global Pricing and Reimbursement Strategy.

Earnshaw, S.R., J.C. Javitt, G.P. Zlateva, A.M. Pleil, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-Effectiveness Model for Age-Related Macular Degeneration: Comparing Early and Late Macugen® Treatment.

Earnshaw, S.R., J.C. Javitt, G.P. Zlateva, A.M. Pleil, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-Effectiveness Model for Age-Related Macular Degeneration: Comparing Macugen® to Visudyne®.

Radigue, C., A. Wolf, A.A. Allshouse, and F. Coste. Costs and Healthcare Consumption in the Abdominally Obese Population.

Gregson, N.N., K.K. Sparrowhawk, and D.M. Mladsi. Global Pricing and Reimbursement Strategy: An Integrated Analytical Framework.

Earnshaw, S.R., J.C. Javitt, C.N. Graham, A.J. Brogan, G.P. Zlateva, S. Shah, and A.P. Adamis. Modeling Treatments for Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Cost-Effectiveness Methods.

Wolowacz, S.E., N.S. Roskell, A. Christie, G. Kerr, and D. Cameron. The cost of hospital care for relapsed breast cancer in the UK based on a large patient-level resource utilisation dataset..

Zhou, X., C. Radigue, F. Maneval, and F. Coste. Validity of Data Collected from an Internet-based Cohort Study.

Fehnel, S.E., L.D. Mcleod, H.M. Edin, and S.L. Hogue. Development and Preliminary Psychometric Evaluation of the Motivation and Energy Inventory – Short Form (MEI-SF).

Tennis, P., B.H. Sherrill, C. Fernandez, and E. Rodriguez. A Meta-Analysis of the Association Between Cancer Risk and Asthma.

Andrews, E.B., K.A. Hollis, D. Miller, P. Tennis, L. Bennett, V.Z. Ameen, A. Heath, D. McSorley, and S.F. Cook. A Patient Follow-up Survey Program for LOTRONEX (Alosetron HCL): Accessing Compliance with the Risk Management Program.

Miller, D., A.M. Walker, J. Avorn, J. Gurwitz, S.F. Cook, A. Feld, and P. Tennis. An Epidemiologic Program for the Study of the Safety and Utilization of LOTRONEX (Alosetron) in the U.S..

Burdett, A.N., C.C. Gard, C.J. Longo, J. Raskin, A. Gilsenan, J.S. Hopkins, and D.P. Miller. Prevalence and Costs of Difficult-to-Treat Depression in a Canadian Claims Database.

Eaton, S.C., E.B. Andrews, K.A. Hollis, J.S. Hopkins, V.Z. Ameen, L. Hamm, A.W. Mangel, R.L. Williams, and S.F. Cook. Prevalence and Demographics of IBS Respondents: Results from a Large Web-Based Survey.

Eaton, S.C., A.W. Mangel, K.A. Hollis, V.Z. Ameen, L.R. Hamm, E.B. Andrews, R.L. Williams, and S.F. Cook. Symptoms of Diarrhea-Predominant or Alternating IBS: An Exploratory Analysis.

Johnson, F.R., and E.B. Andrews. Using Stated-Preference Methods to Inform Pharmaceutical Risk Management.

Lucero, M.A., D. Mladsi, and J. Mauskopf. Communicating the Value: Developing Messages for Payers.

Alten, R.H., B. von Scheele, L. Gaffney, F. Maciver, and L. Niculescu. Cost-Effectiveness of Valdecoxib Compared to Diclofenac in Patients with Rheumatoid Arthiritis (RA) in the United Kingdom (UK) and Germany.

Earnshaw, S.R., S.M. Beard, L. Gaffney, A. Krishnan, and S.L. Hogue. The Impact of Premature Discontinuation of Antidepressant Therapy in Major Depressive Disorder in the UK.

von Scheele, B., K. David, L. Gaffney, L. Niculescu, and K.M. Verburg. The Total Cost of Treatment and the Cost-Effectiveness of Valdecoxib vs Diclofenac in the Treatment of Patients with Osteoarthritis (OA) of the Hip and/or Knee.

Williams, V.S.L., S.E. Fehnel, K.A. Hollis, and S.L. Hogue. Antidepressant-Induced Sexual Dysfunction (ADSD) in Europe: A Preliminary Investigation.

Irish, W., and B. Sherrill. Factors Associated with Chronic Allograft Nephropathy Following Renal Transplantation.

Irish, W., and B. Sherrill. Large-Scale Registry Analysis of the Relative Effect of Discharge Immunosuppression on the Rate of Chronic Allograft Nephropathy Using the Propensity Score Method.

Earnshaw, S.R., A. Krishnan, S.L. Hogue, and J.W. Williams. The Impact of Premature Discontinuation of Antidepressant Therapy in Major Depressive Disorder.

Johnson, F.R., R. Manjunath, and T.J. Hoerger. The Value to High-Risk Patients of Preventing a Case of Diabetes.

Eaton, S.C., S.F. Cook, E.B. Andrews, K.A. Hollis, V.Z. Ameen, A.W. Mangel, and S. Fehnel. Using a Web Panel to Aid Definition of a Target Population to Assist Risk Management.

Gilsenan, A., S. Pedrazzani, L. Bennett, L. Li, W. Yeager, and J.C. Haas. Observational Prevalence Study of HSV-2 (Genital Herpes) in Suburban Primary-Care Practices: Data Collection Procedures and Sampling Methods.

Hauber, A.B., and F.R. Johnson. Risking Health to Avoid Injections.

Mauskopf, J.A., C. Paramore, C.L. Won, and E.H. Snyder. Drug persistence patterns similar for rivastigmine-treated patients and donepezil-treated patients.

Beard, S.M., L. Gaffney, and L. Bamber. Economic Modelling of Antiplatelet Therapy in the Secondary Prevention of Stroke.

von Scheele, B., J. DePlatchett, L. Gaffney, B.M. Peña, and L. Niculescu. The Total Costs of Treatment with Valdecoxib Compared to Generic Diclofenac are Similar in Patients with Rheumatoid Arthritis in Germany.

Johnson, F.R., A.B. Hauber, and J.A. Mauskopf. Willingness to Pay, Willingness to Wait, and Super QALYS.

Rogers, S.M., H.G. Miller, B.H. Forsyth, T.K. Smith, and C.F. Turner. Audio-CASI: The Impact of Operational Characteristics on Data Quality.